PC-004 · GLP-1 · semaglutide
Semaglutide
Ozempic
Also: Wegovy · Rybelsus
§ Overview
A GLP-1 receptor agonist that has revolutionised the treatment of type 2 diabetes and obesity. Semaglutide mimics the incretin hormone GLP-1, reducing appetite, slowing gastric emptying, and improving insulin secretion. It has become one of the most prescribed weight-loss medications globally.
§ Mechanism
Binds to GLP-1 receptors on pancreatic beta cells, stimulating glucose-dependent insulin secretion. Acts on hypothalamic appetite centres to reduce hunger. Delays gastric emptying. The fatty acid chain modification extends half-life by binding to albumin.
§ Common Uses
- → Type 2 diabetes management
- → Weight loss/obesity
- → Cardiovascular risk reduction
- → NASH/fatty liver
§ Reported Side Effects
- · Nausea
- · Vomiting
- · Diarrhea
- · Constipation
- · Abdominal pain
- · Pancreatitis risk (rare)
§ Research, Experiences & Trends
Mechanism of Action
Binds to GLP-1 receptors on pancreatic beta cells, stimulating glucose-dependent insulin secretion. Acts on hypothalamic appetite centres to reduce hunger. Delays gastric emptying. The fatty acid chain modification extends half-life by binding to albumin.
Common Uses
Dosage & Pharmacology
Known Side Effects
- • Nausea
- • Vomiting
- • Diarrhea
- • Constipation
- • Abdominal pain
- • Pancreatitis risk (rare)